Department of Epidemiology & Biostatistics & Ministry of Education Key Lab of Environment & Health, School of Public Health, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei 430030, PR China.
Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430022, PR China.
Epigenomics. 2020 Apr;12(7):605-615. doi: 10.2217/epi-2019-0300. Epub 2020 Mar 17.
To identify patients with colorectal cancer (CRC) who are at a truly higher risk of progression, which is key for individualized approaches to precision therapy. We developed a predictor associated with progression-free interval (PFI) using The Cancer Genome Atlas CRC methylation data. The risk score was associated with PFI in the whole cohort (p < 0.001). A nomogram consisting of the risk score and other significant clinical features was generated to predict the 3- and 5-year PFI in the whole set (area under the curve: 0.79 and 0.71, respectively). The risk score based on 23 DNA-methylation sites may serve as the basis for improved prediction of progression in patients with CRC in future clinical practice.
为了确定真正具有进展高风险的结直肠癌（CRC）患者，这对于精准治疗的个体化方法至关重要。我们使用癌症基因组图谱 CRC 甲基化数据开发了与无进展间隔（PFI）相关的预测因子。风险评分与整个队列的 PFI 相关（p<0.001）。生成了一个包含风险评分和其他重要临床特征的列线图，以预测整个数据集的 3 年和 5 年 PFI（曲线下面积分别为 0.79 和 0.71）。基于 23 个 DNA 甲基化位点的风险评分可能成为未来临床实践中改善 CRC 患者进展预测的基础。
